New CAR-T therapy shows promise for Tough-to-Treat myeloma
NCT ID NCT05172596
First seen Nov 12, 2025 · Last updated May 05, 2026 · Updated 23 times
Summary
This study tested a new treatment called PHE885 for adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The study aimed to see how many patients' tumors shrank or disappeared, but it was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University School of Medicine-Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Fred Hutch Cancer Research
Seattle, Washington, 98109, United States
-
Novartis Investigative Site
Camperdown, New South Wales, 2050, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Salvador, Estado de Bahia, 41253-190, Brazil
-
Novartis Investigative Site
São Paulo, São Paulo, 01509-900, Brazil
-
Novartis Investigative Site
Calgary, Alberta, T2N 5G2, Canada
-
Novartis Investigative Site
Lille, 59037, France
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Poitiers, 86021, France
-
Novartis Investigative Site
Würzburg, Bavaria, 97080, Germany
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Hamburg, 20246, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Athens, 106 76, Greece
-
Novartis Investigative Site
Thessaloniki, 570 10, Greece
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Bologna, BO, 40138, Italy
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4678602, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 060 8648, Japan
-
Novartis Investigative Site
Kyoto, Kyoto, 602-8566, Japan
-
Novartis Investigative Site
Sendai, Miyagi, 980 8574, Japan
-
Novartis Investigative Site
Riyadh, 11211, Saudi Arabia
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Pamplona, Navarre, 31008, Spain
-
Novartis Investigative Site
Salamanca, 37007, Spain
-
Novartis Investigative Site
Glasgow, Scotland, G51 4TF, United Kingdom
-
Novartis Investigative Site
Birmingham, West Midlands, B15 2TH, United Kingdom
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.